Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 7/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17347759 | 0.87 | NAMPT (0.41) | NAMPTNPC1ALDH1A1 | |
| SCHEMBL17337354 | 0.85 | NAMPT (0.42) | NAMPTNPC1ALDH1A1 | |
| SCHEMBL17337351 | 0.85 | NAMPT (0.42) | NAMPTNPC1ALDH1A1 | |
| SCHEMBL19663651 | 0.82 | MTNR1A (0.32) | — | |
| SCHEMBL22667381 | 0.81 | MTNR1A (0.41) | NAMPTALDH1A1 | |
| SCHEMBL23837376 | 0.80 | SMYD3 (0.34) | — | |
| SCHEMBL23837287 | 0.80 | MTNR1A (0.35) | — | |
| SCHEMBL23837279 | 0.80 | MTNR1A (0.33) | — | |
| SCHEMBL18797977 | 0.79 | — | — | |
| SCHEMBL20053172 | 0.79 | ITGB3 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008346-B2 | Beta-lactamase inhibitors | VenatoRx Pharmaceuticals, Inc. (US) | 2021-05-18 | — | — | US | disclosed |
| US-20200361962-A1 | BETA-LACTAMASE INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008346-B2 | Beta-lactamase inhibitors | MGAM, GAA, LCT | NAMPT 1369/4885NPC1 4491/4885SCN9A 1985/4885 |
| US-20200361962-A1 | BETA-LACTAMASE INHIBITORS | MGAM, GAA, LCT | NAMPT 1369/4885NPC1 4491/4885SCN9A 1985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.